Clinical Trial: NCT03878823
Safety and Pharmacokinetics of ODM-209
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Orion Corporation, Orion Pharma |
| Information Provided By: | Orion Corporation, Orion Pharma |
| Last Update Posted: | 2024-02-01 |
Study Overview
Brief Summary
The purpose of this first-in-human study is to evaluate safety and tolerability of ODM-209 and find the dose of ODM-209.
Official Title
Safety and Pharmacokinetics of ODM-209 in Patients With Metastatic Castration-resistant Prostate Cancer or Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Conditions
Prostate Cancer Metastatic, Advanced Breast Cancer, Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Intervention / Treatment
- Drug: ODM-209
Other Study ID Numbers
- 3125001
Start Date (Actual)
2019-04-17
Primary Completion Date (Actual)
2024-01-09
Study Completion Date (Actual)
2024-01-09
Enrollment (Actual)
38
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Orion Corporation, Orion Pharma |
| Information Provided By: | Orion Corporation, Orion Pharma |
| Last Update Posted: | 2024-02-01 |
Study Overview
Brief Summary
The purpose of this first-in-human study is to evaluate safety and tolerability of ODM-209 and find the dose of ODM-209.
Official Title
Safety and Pharmacokinetics of ODM-209 in Patients With Metastatic Castration-resistant Prostate Cancer or Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Conditions
Prostate Cancer Metastatic, Advanced Breast Cancer, Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Intervention / Treatment
- Drug: ODM-209
Other Study ID Numbers
- 3125001
Start Date (Actual)
2019-04-17
Primary Completion Date (Actual)
2024-01-09
Study Completion Date (Actual)
2024-01-09
Enrollment (Actual)
38
Study Type
Interventional
Phase
Phase 1, Phase 2